CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.

However, when chemotherapy-treated or untreated biphasic MPM patients were grouped according to CD157 H-score, the group with chemotherapy and CD157 H-score >50 showed a clear trend towards shorter survival than the group with chemotherapy and CD157 H-score ≤50, although the difference was not statistically significant (log-rank test p = 0.062) (Fig. 5C ).

also in 12,254 other papers